Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

First Contract Win for Instem Clinical

2 Jul 2013 07:00

RNS Number : 3502I
Instem plc
02 July 2013
 

2 July 2013

Embargoed for 07:00

Instem plc

("Instem", the "Company" or the "Group")

First Contract Win for Instem Clinical

Instem plc (AIM: INS.L), a leading provider of IT applications to the global early development healthcare market, is pleased to announce its first contract win for its newly acquired ALPHADAS software. The contract consists of a high six-figure GBP perpetual licence plus implementation services, with ongoing annual support and maintenance.

ALPHADAS,the market leading, e-source data capture ("EDC") system and site automation software suite for early phase clinical studies, has been selected by a UK-based global leader in the provision of specialisedclinical services. ALPHADAS is now offered by Instem Clinical, formerly Logos Technologies, which was acquired by Instem in May 2013.

Replacing a more traditional 'form based' EDC system, ALPHADAS was selected for its ability to deliver an immediate and significant return on investment within the client's highly complex studies. ALPHADAS sources data direct from instrumentation, removes errors at source, tracks samples from collection to dispatch and enables critical real time data review. Further efficiencies are also delivered by ALPHADAS through its ability to track study subjects throughout the recruitment process, staff resourcing and site management and the provision of a fully visible audit trail.

Phil Reason, CEO of Instem plc, commented, "We are delighted to be able to announce a significant contract win for Instem Clinical, so quickly after it was established following the acquisition of Logos in May this year. A leader in their field and experiencing significant growth, the new client is currently working with some of the world's foremost pharmaceutical and research companies. This is a clear demonstration of the quality of the ALPHADAS software and the opportunity to expand Instem's market to early clinical studies."

For further information, please contact:

Instem plc

+44 (0) 1785 825 600

Phil Reason, CEO

Nigel Goldsmith, CFO

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Aubrey Powell

Joe Stroud

Newgate Threadneedle

+44 (0) 20 7653 9850

Caroline Evans-Jones

Fiona Conroy

 

About Instem plc

Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are used by customers worldwide, meeting the rapidlyexpanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem supports its clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan.

To learn more about Instem solutions and its mission, please visit www.instem.com or its investor centre http://investors.instem.com/

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTUGUAWMUPWPGG
Date   Source Headline
15th Feb 201811:05 amRNSSecond Price Monitoring Extn
15th Feb 201811:00 amRNSPrice Monitoring Extension
29th Jan 20187:00 amRNSDirector/PDMR Shareholding
23rd Jan 20185:27 pmRNSHolding(s) in Company
16th Jan 20187:01 amRNSContract Win
16th Jan 20187:00 amRNSTrading Statement
5th Oct 201711:30 amRNSHolding(s) in Company
29th Sep 201712:17 pmRNSIssue of Equity & Total Voting Rights
26th Sep 20177:00 amRNSHalf-year Report
21st Sep 20175:57 pmRNSHolding(s) in Company
4th Sep 20177:00 amRNSNotice of Results
31st May 20178:39 amRNSPayment of consideration and total voting rights
19th May 20175:00 pmRNSHolding(s) in Company
18th May 201710:24 amRNSResult of AGM
9th May 20172:25 pmRNSIssue of Equity and Total Voting Rights
28th Apr 20175:12 pmRNSHolding(s) in Company
26th Apr 20177:00 amRNSUS Government Contract
21st Apr 20177:00 amRNSPosting of Annual Report and Notice of AGM
4th Apr 201710:10 amRNSHolding(s) in Company
4th Apr 201710:10 amRNSHolding(s) in Company
29th Mar 20173:46 pmRNSHolding(s) in Company
28th Mar 20177:00 amRNSFinal Results
9th Mar 20177:00 amRNSInvestor Teach-in
7th Mar 20177:00 amRNSNotice of Results
16th Jan 20177:00 amRNSTrading Statement
9th Jan 20172:30 pmRNSAppointment of Chief Operating Officer
9th Jan 20177:00 amRNSGrowth & Innovation Forum
20th Dec 20165:23 pmRNSHolding(s) in Company
19th Dec 20164:58 pmRNSHolding(s) in Company
15th Dec 20167:00 amRNSRevised Earn Out Settlement
21st Nov 20167:00 amRNSTrading Statement
22nd Sep 20167:00 amRNSHolding(s) in Company
21st Sep 20168:08 amRNSIssue of Equity
19th Sep 20167:00 amRNSHalf-year Report
5th Sep 20163:40 pmRNSEarnings Enhancing Acquisition of Notocord®
24th Aug 20167:00 amRNSTrading Update and Notice of Half-Year Results
9th Jun 20165:32 pmRNSIssue of Equity
1st Jun 20161:55 pmRNSHolding(s) in Company
31st May 20167:00 amRNSAcquisition, Issue of Equity & Total Voting Rights
26th May 20165:42 pmRNSResult of AGM
19th May 20162:31 pmRNSHolding(s) in Company
16th May 20164:30 pmRNSIssue of Equity and Total Voting Rights
7th Apr 20169:42 amRNSHolding(s) in Company
5th Apr 20167:00 amRNSFinal Results
4th Apr 20167:00 amRNSFour SEND related contract wins
15th Mar 20167:00 amRNSTwo SEND Submit Contract Wins
14th Mar 20167:00 amRNSNotice of Results
3rd Mar 201610:56 amRNSHolding(s) in Company
29th Feb 20169:56 amRNSHolding(s) in Company (Correction)
26th Feb 20169:26 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.